Cogstate Ltd. is a global cognitive science company. The firm optimizes brain health assessments to develop new medicines and to enable earlier clinical insights in healthcare. The Company’s technologies provide computerized cognitive tests across a list of domains and support electronic clinical outcome assessment (eCOA) solutions. The firm operates through two segments: Clinical Trials and Healthcare. Its Clinical Trials segment’s solutions guide various researchers across many indications and all phases of development. The company helps clinical trial partners to optimize outcomes with the help of its computerized cognitive tests, rater training and data quality programs, and study design insights from scientists. Its Healthcare segment provides tools to screen and monitor cognitive changes in the clinical and community settings.
CogState (ASX: CGS)
- Home
- CogState (ASX: CGS)
Here are the latest articles on CogState (ASX: CGS)
Cogstate buys back exclusive rights to its brain health testing tech from Eisai
April 2, 2024
Neuroscience tech company Cogstate (ASX: CGS) has re-acquired the global rights to its technology previously exclusively licensed to Japanese pharma company and its global commercial partner, Eisai. The agreement excludes Japan and will come into effect on April 1, 2024. This marks an amendment to the duo’s 2020 agreement, which includes exclusivity across a few
Recent Articles
